An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration

Cancer Research

Volumn 58, Issue 8, 1998, Pages 1677-1683

  Sato, Tsutomu ^a   Yamauchi, Naofumi ^a   Sasaki, Hiroyoshi ^a   Takahashi, Minoru ^a   Okamoto, Tetsuro ^a   Sakamaki, Sumio ^a   Watanabe, Naoki ^a   Niitsu, Yoshiro ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PANCREAS CANCER; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; APOPTOSIS; GENE THERAPY; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, NUDE; MUTAGENESIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032522817     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Watanabe, N., Yamauchi, N., Maeda, M., Neda, H., Tsuji, Y., Okamoto, T., Tsuji, N., Akiyama, S., Sasaki, H., and Niitsu, Y. Recombinant human tumor necrosis factor causes regression in patients with advanced malignancies. Oncology, 51: 360-365, 1994.
2. Okamoto, T., Watanabe, N., Yamauchi, N., Tsuji, Y., Itoh, Y., Neda, H., and Niitsu, Y. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res., 52: 5278-5281, 1992.
3. Watanabe, N., Tsuji, N., Tsuji, Y., Sasaki, H., Okamoto, T., Akiyama, S., Kobayashi, D., Sato, T., Yamauchi, N., and Niitsu, Y. Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and Adriamycin in pancreatic carcinoma cells. Pancreas, 13: 395-400, 1996.
4. Tartaglia, L. A., Ayres, T. M., Wong, G. H. W., and Goeddel, D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell, 74: 845-853, 1993.
5. Barbara, J. A. J., Smith, W. B., Gamble, J. R., Van-Ostade, X., Vandenabeele, P., Tavernier, J., Fiers, W., Vades, M. A., and Lopez, A. F. Dissociation of TNF α cytotoxic and proinflammatory activities by p55 receptor-and p75 receptor-selective TNF α mutants. EMBO J., 13: 843-850, 1994.
6. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P., and Fiers, W. Human TNF mutants with selective activity on the p55 receptor. Nature (Lond.), 361: 266-269, 1993.
7. Soma, G-I., Kitakara, N., Tsuji, Y., Kato, M., Oshima, H., Gatanaga, T., Inagawa, H., Noguchi, K., Tanabe, Y., and Mizuno, D. Improvement of cytotoxicity of tumor necrosis factor (TNF) by increase in basicity of its N-terminal region. Biochem. Biophys. Res. Commun., 148: 629-635, 1987.
8. Xi, T., Shi, X., Guo, D., Dong, X., Xu, X., and Zhu, D. Biological activities of human tumor necrosis factor-α and its novel mutants. Biochem. Mol. Biol. Int., 38: 1183-1189, 1996.
9. Nakamura, S., Kato, A., Masegi, T., Fukuoka, M., Kitai, K., Ogawa, H., Ichikawa, Y., Maeda, M., Watanabe, N., Kohgo, Y., and Niitsu, Y. A novel recombinant tumor necrosis factor α mutant with increased anti-tumor activity and lower toxicity. Int. J. Cancer, 48: 744-748, 1991.
10. Masegi, T., Kato, A., Kitai, K., Fukuoka, M., Ogawa, H., Ichikawa, Y., Nakamura, S., Watanabe, N., and Niitsu, Y. Characterization of a novel human tumor necrosis factor α mutant with increased cytotoxic activity. Jpn. J. Cancer Res., 86: 72-80, 1995.
11. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.
12. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
13. Barba, D., Hardin, J., Sadelain, M., and Gage, F. H. Development of anti-tumor immunity following thymidine kinase mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA, 91: 4348-4352, 1994.
14. Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. In vivo analysis of the "bystander effect": a cytokine cascade. Exp. Hematol., 24: 829-838, 1996.
15. Chen, S. H., Kosai, K., Xu, B., Pham-Nguyen, K., Contant, C., Finegold, M. J., and Woo, S. L. C. Combination suicide and cytokine gene therapy for hepatic metastasis of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res., 56: 3785-3762, 1996.
16. Naume, B., Shalaby, R., Lesslauer, W., and Espevik, T. Involvement of the 55-and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J. Immunol., 146: 3045-3048, 1991.
17. Pfizenmaier, K., Scheurich, P., Schluter, C., and Kronke, M. Tumor necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumor cells. J. Immunol., 138: 975-980, 1987.
18. Flesch, I. E. A., Hess, J. H., Huang, S., Aguet, M., Rothe, J., Bluethmann, H., and Kaufmann, S. H. E. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon γ and tumor necrosis factor α. J. Exp. Med., 181: 1615-1621, 1995.
19. Loetscher, H., Pan, Y. C. E., Lahm, H. W., Gentz, R., Brockhaus, M., Tabuchi, H., and Lesslauer, W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell, 61: 351-359, 1990.
20. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA, 84: 7413-7417, 1987.
21. Manfred, B., Hans, J. S., Ernst, J. S., Willi, H., Werner, L., and Hansruedi, L. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 87: 3127-3131, 1990.
22. Hermann, M., Lorenz, H. M., Voll, R., Grunke, M., Woith, W., and Kalden, J. R. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucl. Acids Res., 22: 5506-5507, 1994.
23. Geng, Y. J., and Libby, P. Evidence for apoptosis in advanced human atheroma: colocalization with interleukin-1b-converting enzyme. Am. J. Pathol., 147: 251-266, 1995.
24. Kadish, S. A., Doyle, T. A., Steinhauer, H. E., and Ghossein, N. A. Natural cytotoxicity and interferon production in human cancer: efficient natural killer activity and normal interferon production in patients with advanced disease. J. Immunol., 127: 1817-1822, 1981.
25. Niitsu, Y., Watanabe, N., Neda, H., Yamauchi, N., Maeda, M., Sone, H., and Kuriyama, H. Induction of synthesis of tumor necrosis factor in human and murine cell lines by exogenous recombinant human tumor necrosis factor. Cancer Res., 48: 5407-5410, 1988.
26. Himeno, T., Watanabe, N., Yamauchi, N., Maeda, M., Tsuji, Y., Okamoto, T., Neda, H., and Niitsu, Y. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res., 50: 4941-4945, 1990.
27. Wong, G. H. W., and Goeddel, D. V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (Washington DC), 242: 941-944, 1988.
28. Wong, G. H. W., Elwell, J. H., Oberley, L. M., and Goeddel, D. V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxiciy of tumor necrosis factor. Cell, 58: 923-931, 1988.
29. Dbaibo, G. S., Perry, D. K., Gamard, C. J., Platt, R., Poirier, G. G., Obeid, L. M., and Hannun, Y. A. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med., 185: 481-490, 1997.
30. Kumakura, S., Ishikura, H., Tsumura, H., Iwata, Y., Endo, J., and Kobayashi, S. c-Myc, and Bcl-2 protein expression during the induction of apoptosis and differentiation in TNF α-treated HL-60 cells. Leuk. Lymphoma, 23: 383-394, 1996.
31. Beg, A. A., and Baltimore, D. An essential role for NE-κB in preventing TNF-α-induced cell death. Science (Washington DC), 274: 782-784, 1996.
32. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
33. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science (Washington DC), 274: 787-789, 1996.
34. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD59 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
35. Hsu, H., Xiong, J., and Goeddel, D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell, 81: 495-504, 1995.
36. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem., 270: 7795-7798, 1995.
37. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81: 505-512, 1995.
38. Enari, M., Hug, H., and Nagata, S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (Lond.), 375: 78-81, 1995.
39. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95(Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
40. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.
41. Rothe, M., Wong, S. C., Henzel, W. J., and Goeddel, D. V. A novel family of putative signal transducers associated with the cytoplasmic domain of 75 kDa tumor necrosis factor receptor. Cell, 78: 681-692, 1994.
42. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science (Washington DC), 269: 1424-1427, 1995.
43. Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature (Lond.), 385: 540-544, 1997.
44. Van Ostade, X., Vandenabeele, P., Tavernier, J., and Fiers, W. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur. J. Biochem., 220: 771-779, 1994.
45. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
46. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271: 12687-12690, 1996.
47. Pan, G., Ni, J., Wei, Y-F., Yu, G-L., Gentz, R., and Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (Washington DC), 277: 815-818, 1997.
48. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (Washington DC), 277: 818-821, 1997.